As part of a double-blind study of medication treatment for opioid dependence during pregnancy, 17 opioid-dependent pregnant women maintained on either buprenorphine or methadone underwent fetal monitoring at 24, 28, 32, and 36 weeks gestation. Maternal demographic information and infant outcomes did not significantly differ by medication group. Earlier in gestation (24 and 28 weeks), buprenorphine-exposed fetuses had higher levels of fetal heart rate variability, more accelerations in fetal heart rate and greater coupling between fetal heart rate and fetal movement than the methadone-exposed group (all p's <.05). Later in gestation (32 and 36 weeks), buprenorphine-exposed fetuses displayed less suppression of motor activity and longer duration of movements than the methadone-exposed group (all p's <.05). These results may have implications for the optimal treatment of the opioid-dependent pregnant woman. Keywords buprenorphine; drug dependency; fetal heart rate; fetus; methadone; opioids; pregnancy © 2010 Elsevier Inc. All rights reserved.Corresponding author: Lauren M. Jansson, The Center for Addiction and Pregnancy, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, D5, Baltimore, MD 21224, Phone: 410-550-5438, Fax: 410-550-2713, ljansson@jhmi.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONFLICT OF INTEREST STATEMENT FOR AUTHORSThe authors have no conflicts of interest to report.
NIH Public Access
INRODUCTIONOpioid dependency, both use of illicit opioids and misuse of licit opioids, during pregnancy remains a public health dilemma internationally. Opioid dependent pregnant women comprise a special population due to the multiple considerations of the mother, the pregnancy, and the fetus. Maintenance treatment with methadone, a full mu-agonist, is the current recommended standard of care for the opioid dependent pregnant woman [16], offering many well-known benefits for the mother-infant dyad [6]. However, research from animal and human studies has raised concerns regarding short-and long-term adverse effects. Animal literature has shown that prenatal methadone exposure predicates a disruption to neural maturation in exposed fetuses [21,22], and there is evidence of similar disruption in human neurodevelopment. When compared to non-exposed fetuses, methadone-exposed fetuses have reduced baseline heart rate, proportion of accelerations [17,20], and heart rate variability [20]. At times of maternal peak methadone levels, methadone-exposed fetuses have less motor activity [24,10] slower and less variabl...